| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| AZN | Astrazeneca PLC | $33.95 | $85.96B | Uptrend |
Eli Lilly Is An Attractive Buy For 2018
https://seekingalpha.com/article/4198036-eli-lilly-attractive-buy-2018?source=feed_sector_healthcare
Aug 11, 2018 -
0
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
http://www.zacks.com/stock/news/317383/pharma-stock-roundup-nvo-q2-earnings-jnj-agn-azns-pipeline-updates-in-focus?cid=CS-ZC-FT-317383
Aug 10, 2018 - Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
0
Wall Street Breakfast: Fed, Apple, Tariffs
https://seekingalpha.com/article/4192931-wall-street-breakfast-fed-apple-tariffs?source=feed_tag_wall_st_breakfast
Aug 01, 2018 -
0
Wall Street Breakfast: Facebook Takes The FANGs Out
https://seekingalpha.com/article/4190327-wall-street-breakfast-facebook-takes-fangs?source=feed_tag_wall_st_breakfast
Jul 26, 2018 - Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes, Stitcher and SoundCloud (click the highlighted links). The tech-heavy Nasdaq is set for a big down
0
Vaccinex Readies $45 Million U.S. IPO
https://seekingalpha.com/article/4190170-vaccinex-readies-45-million-u-s-ipo?source=feed_sector_healthcare
Jul 25, 2018 - Vaccinex has filed proposed terms for a $45 million IPO of its common stock. The firm is developing potential treatments for Huntington's Disease and non-small cell lung cancer based on its VX15 candi
0
Roche Successful In Front-Line Lung Cancer, Should Merck Be Worried?
https://seekingalpha.com/article/4189402-roche-successful-front-line-lung-cancer-merck-worried?source=feed_sector_healthcare
Jul 24, 2018 - Roche announces that the co-primary endpoint of progression-free survival in its phase 3 study treating patients with front-line advanced non-squamous non-small cell lung cancer had been met. The prog
0
AstraZeneca Sells Atacand's European Rights to Cheplapharm
http://www.zacks.com/stock/news/313066/astrazeneca-sells-atacands-european-rights-to-cheplapharm?cid=CS-ZC-FT-313066
Jul 24, 2018 - AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.
0
Company Profile: Surface Oncology
https://seekingalpha.com/article/4189007-company-profile-surface-oncology?source=feed_sector_healthcare
Jul 22, 2018 - SURF has a business-minded management with a strong track record of raising capital, shoring up its balance sheet with $200 million cash through its spring IPO and partnership w/ Novartis.The company'
0
Ironwood Begins New Phase III Study to Expand Linzess Label
http://www.zacks.com/stock/news/311847/ironwood-begins-new-phase-iii-study-to-expand-linzess-label?cid=CS-ZC-FT-311847
Jul 17, 2018 - Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.
0
Biotech Analysis Central Pharma News: Cytodyn's Acquisition, Novartis Exits Antibotic Research, Advaxis' FDA Hold Removed
https://seekingalpha.com/article/4187330-biotech-analysis-central-pharma-news-cytodyns-acquisition-novartis-exits-antibotic-research?source=feed_sector_healthcare
Jul 15, 2018 - Cytodyn announced it will acquire ProstaGene LLC. Novartis bows out of antibiotic development programs. Advaxis announced that FDA clinical hold for cervical cancer program had been removed.
1
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| ABT | Abbott Laboratories | NYSE | $52.51 | $91.23B |
| LLY | Eli Lilly and Company | NYSE | $83.91 | $92.38B |
| GSK | GlaxoSmithKline PLC | NYSE | $40.58 | $99.79B |
| AGN | Allergan plc. | NYSE | $204.65 | $68.42B |
| BMY | Bristol-Myers Squibb Company | NYSE | $63.36 | $103.91B |